Matters of legal in nature including licensing, intellectual property, and lawsuits.
–Patent No. 1802752 “Parellel Patch Clamp System” Upheld in European Patent Office- Sunnyvale, California – October 7, 2016. Molecular Devices, LLC, a company committed to providing innovative analytical solutions for protein and cell biology, announced today that its European Patent No. 1802752 titled “Parallel Patch Clamp System” was upheld by the European Patent Office in... Read more
CHALFONT ST. GILES, UK – 30 September 2016 –At the International Society for Cellular Therapy’s Regional Meeting in Memphis, TN, GE Healthcare’s recently acquired Biosafe Group introduces Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing and final formulation during cell processing. Combined with GE... Read more
Evry, France, and Bergisch Gladbach, Germany, September 28th, 2016 – Genethon, a leader in the field of gene therapy treatments for rare diseases, and Miltenyi Biotec, a global front-runner in cell processing and related technologies in cell therapy, have announced the execution of an exclusive license to the patents and trademarks for the development and commercialization... Read more
Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Neurons iCell Astrocytes iCell DopaNeurons iCell GlutaNeurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts iCell Endothelial Cells... Read more
Chalfont St Giles, UK – 23 August 2016 – In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of... Read more
Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma Kusatsu/Shiga, Japan — June 21, 2016 – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with Kite Pharma, Inc. (“Kite”), United States, under which Takara Bio grants Kite a commercial license to use applicable patents relating... Read more
Monroe, NC- June 15, 2016 Greiner Bio-One North America, Inc. is proud to announce the release of a new line of small laboratory equipment products which includes a Vortex Mixer, Mini Block Heater, Mini Centrifuge, Microplate Centrifuge, Mini Vortex Mixer, and Sapphire Maxipette. These products are used worldwide in medical and research laboratories and Greiner... Read more
CHALFONT ST. GILES, UK and KINGSTON, ONTARIO, CANADA – 8 June 2016 – PnuVax Incorporated (PnuVax), a vaccine and biopharmaceutical company, and GE Healthcare’s Life Sciences business (NYSE: GE) announced today that they have entered an agreement under which PnuVax can acquire GE Healthcare’s intellectual property (IP) relating to an inactivated yellow fever vaccine. Under... Read more
2016 2016/03/22 Takara Bio grants Cellectis SA a commercial license to use RetroNectin® Kusatsu/Shiga, Japan – March 22, 2016 – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with Cellectis SA. Under the agreement, Takara Bio grants Cellectis a commercial license to use RetroNectin® and Takara Bio also supplies RetroNectin® to Cellectis . ... Read more
WAUWATOSA, Wis., Dec. 7, 2015 – The National Basketball Association (NBA) and GE Healthcare (NYSE: GE) today conducted a successful meeting at GE’s Wisconsin offices to discuss the progress of their research collaboration. The partnership, which commenced in July, promotes sports medicine research to benefit not only NBA players but athletes of all levels. Today’s... Read more